Seelos therapeutics announces closing of public offering of common stock and full exercise of underwriter's option to purchase additional shares

New york, jan. 28, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten...
SEEL Ratings Summary
SEEL Quant Ranking